@entity2399 reduces XXXX size when administered before but not after coronary reperfusion in a canine model.

@entity5045 @entity2399 @entity73260 @entity1563 @entity1188 @entity583 @entity1760
BACKGROUND: The role of @entity1760 in treating @entity583 ( @entity583 ) has been controversial. Several small clinical trials indicate that @entity1760 may have a role in treating @entity583 early, whereas the other results suggest that @entity1760 is of questionable benefit. METHODS AND RESULTS: We looked at the effect of @entity1760 on @entity1188 size (IS) when given during a @entity1563 and after reperfusion. @entity2399 ( @entity73260 bolus plus 2 mEq/h for 5 hours) was given at 15 or 45 minutes of @entity1563 or 15 minutes of reperfusion. The left anterior descending coronary artery was occluded for 90 minutes, followed by 300 minutes of reperfusion. IS to area at risk (IS/AR) was measured by planimetry after @entity5045 staining. Collateral myocardial blood flow was measured with radioactive microspheres. The IS/AR ratio in the control group was 52.3 +/- 19.6% compared with 20.5 +/- 11.7% and 21.3 +/- 6.5% at 15 and 45 minutes of occlusion, respectively (P < .05). There were no significant differences in the reduction in IS at 15 and 45 minutes of occlusion. Although there was a reduction in the IS when @entity1760 was administered during reperfusion (38.2 +/- 13.4%), it was not statistically significant. There was no significant difference in the AR relative to the total left ventricular weight between the four groups. CONCLUSIONS: The data suggest that @entity1760 infusion during a @entity1563 has a significant benefit in reducing the IS in this model. @entity1760 may have a beneficial clinical role in @entity583 , especially if administered before reperfusion as a bolus followed by a constant infusion.
